ERBB2 and neoplasm: As the effects of anti-ErbB2 mAb therapy are also mediated by the immune system, through mechanisms including antibody-dependent cellular cytotoxicity (ADCC), we investigated whether modulating FA metabolism affected anti-tumor immune responses in our model61–63.